Document Type

Article

Publication Date

2-1-2019

Keywords

JGM

JAX Source

Biomark Insights 2019 Feb 1; 14:1177271919826545

Volume

14

First Page

1177271919826545

Last Page

1177271919826545

ISSN

1177-2719

PMID

30745794

DOI

https://doi.org/10.1177/1177271919826545

Abstract

The standard of care in oncology has been genomic profiling of tumor tissue biopsies for the treatment and management of disease, which can prove to be quite challenging in terms of cost, invasiveness of procedure, and potential risk for the patient. As the number of available drugs in oncology continues to increase, so too does the demand for technologies and testing applications that can identify genomic alterations targetable by these new therapies. Liquid biopsies that use a blood draw from the diseased patient may offset the many disadvantages of the invasive procedure. However, as with any new technology or finding in the clinical field, the clinical utility of an analytical test such as that of the liquid biopsy has to be established. Here, we review the clinical testing space for liquid biopsy offerings and elucidate the technical and regulatory considerations to develop such an assay, using our recently validated PlasmaMonitor

Comments

The authors gratefully acknowledge Jane Cha (JAX Creative Design) for the graphics and schematic presented in Figure 1.

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License.

Download

Share

COinS